is a Combination of and for the Treatment of Form

Instructions and help about Is A Combination Of And For The Treatment Of

right so at the plenary session the theme seems to be combination therapy so very exciting because we really don't have any combination therapy for prostate cancer yet and so for mcrpc there's going to be another study using another parp inhibitor neraparib in combination again with abaraderone and the details will be discussed during the meeting so that'll further our knowledge to the combination and in mhsbc we have a large pivotal study looking at improving survival by combining dosa taxal and derolutamide and in that scenario there was a clear advantage in terms of overall survival of the combination of dosa taxal and daryl ludamide one of the ar targeted therapies that is presently used for non-metastatic crpc and and this is compared to dose taxal and adt alone and and so overall we're able to improve overall survival and the other endpoints also whether patients presented with upfront metastatic disease or present presented with localized disease that progressed to mhsbc patient